# Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

> **NCT05580042** · PHASE1 · COMPLETED · sponsor: **TWi Biotechnology, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Granuloma Annulare

## Interventions

- **DRUG:** AC-1101

## Key facts

- **NCT ID:** NCT05580042
- **Lead sponsor:** TWi Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2023-11-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580042, "Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05580042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*